Zhao, Yujun; Aguilar, Angelo; Bernard, Denzil; Wang, Shaomeng published an article on February 12 ,2015. The article was titled 《Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment》, and you may find the article in Journal of Medicinal Chemistry.Name: 1-(3-(Methylsulfonyl)propyl)piperazine dihydrochloride The information in the text is summarized as follows:
A review. Design of small-mol. inhibitors (MDM2 inhibitors) to block the MDM2-p53 protein-protein interaction has been pursued as a new cancer therapeutic strategy. In recent years, potent, selective, and efficacious MDM2 inhibitors have been successfully obtained and seven such compounds have been advanced into early phase clin. trials for the treatment of human cancers. Here, we review the design, synthesis, properties, preclin., and clin. studies of these clin.-stage MDM2 inhibitors. In the part of experimental materials, we found many familiar compounds, such as 1-(3-(Methylsulfonyl)propyl)piperazine dihydrochloride(cas: 939983-66-1Name: 1-(3-(Methylsulfonyl)propyl)piperazine dihydrochloride)
1-(3-(Methylsulfonyl)propyl)piperazine dihydrochloride(cas: 939983-66-1) is a member of sulfones.The sulfones, like the sulfonamides, are structural analogs of para-aminobenzoic acid that interfere with folic acid metabolism by acting as competitive inhibitors of dihydropteroate synthetase. All sulfones of clinical value are derivatives of dapsone, the most widely used member of this class.Name: 1-(3-(Methylsulfonyl)propyl)piperazine dihydrochloride
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics